Pfizer (NYSE:PFE) Trading Up 2% After Analyst Upgrade

Shares of Pfizer Inc. (NYSE:PFE) rose 2% on Tuesday after Guggenheim raised their price target on the stock from $33.00 to $35.00. Guggenheim currently has a buy rating on the stock. Pfizer traded as high as $25.97 and last traded at $25.7250. 38,945,952 shares were traded during mid-day trading, a decline of 24% from the average daily volume of 51,583,180 shares. The stock had previously closed at $25.22.

Other equities analysts have also issued research reports about the stock. UBS Group reiterated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $26.00 price target on shares of Pfizer in a report on Wednesday, November 5th. Scotiabank initiated coverage on Pfizer in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price objective on the stock. Bank of America upped their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Finally, Morgan Stanley dropped their target price on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $28.39.

Hedge Funds Weigh In On Pfizer

A number of large investors have recently bought and sold shares of PFE. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer in the first quarter worth about $27,000. Curio Wealth LLC boosted its position in Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares during the period. Bayforest Capital Ltd bought a new position in Pfizer in the 1st quarter worth about $28,000. Grey Fox Wealth Advisors LLC purchased a new position in shares of Pfizer during the third quarter worth approximately $29,000. Finally, Harbor Asset Planning Inc. bought a new stake in shares of Pfizer during the second quarter valued at approximately $29,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 2.0%

The stock has a market cap of $146.26 billion, a PE ratio of 13.68, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. The business has a fifty day moving average of $24.91 and a 200-day moving average of $24.54. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. The ex-dividend date is Friday, November 7th. Pfizer’s payout ratio is presently 100.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.